Table 2.
Comparison of MR imaging data according to SD and LD types
| MR imaging data | Total (n = 140) | SD type (n = 93) | LD type (n = 47) | p value |
|---|---|---|---|---|
| Median size, cm* | 4.7 (1.2–16.8) | 4.3 (1.2–16.8) | 5.2 (1.8–14.2) | 0.055 |
| Location (center) | ||||
| Peripheral | 120 (85.7) | 82 (88.2) | 38 (80.9) | 0.110 |
| Midzone | 13 (9.3) | 9 (9.7) | 4 (8.5) | |
| Central/diffuse | 7 (5.0) | 2 (2.2) | 5 (10.6) | |
| Location (perihilar border) | ||||
| Peripheral | 65 (46.4) | 53 (57.0) | 12 (25.5) | 0.001 |
| Midzone | 26 (18.6) | 16 (17.2) | 10 (21.3) | |
| Central/diffuse | 49 (35.0) | 24 (25.8) | 25 (53.2) | |
| Contour | ||||
| Round/lobulated | 119 (85.0) | 90 (96.8) | 29 (61.7) | <0.001 |
| Infiltrative | 21 (15.0) | 3 (3.2) | 18 (38.3) | |
| Liver surface change | 44 (31.4) | 32 (34.4) | 12 (25.5) | 0.285 |
| BD dilatation | ||||
| No dilatation | 73 (52.1) | 64 (68.8) | 9 (19.1) | <0.001 |
| Peritumoral dilatation | 60 (42.9) | 27 (29.0) | 33 (70.2) | |
| Diffuse dilatation | 7 (5.0) | 2 (2.2) | 5 (10.6) | |
| Liver cirrhosis | 44 (31.4) | 29 (31.2) | 15 (31.9) | 0.930 |
| AP enhancement pattern | ||||
| Nonrim APHE | 33 (23.6) | 25 (26.9) | 8 (17.0) | <0.001 |
| Rim APHE | 84 (60.0) | 64 (68.8) | 20 (42.6) | |
| No APHE | 23 (16.4) | 4 (4.3) | 19 (40.4) | |
| Peritumoral arterial enhancement | 93 (66.4) | 55 (59.1) | 38 (80.9) | 0.010 |
| Delayed central enhancement | 107 (76.4) | 69 (74.2) | 38 (80.9) | 0.381 |
| Portal phase washout pattern | ||||
| No washout | 86 (61.4) | 51 (54.8) | 35 (74.5) | 0.015 |
| Peripheral washout | 23 (16.4) | 21 (22.6) | 2 (4.3) | |
| Nonperipheral washout | 31 (22.1) | 21 (22.6) | 10 (21.3) | |
| TP appearance | ||||
| No hypointensity | 72 (51.4) | 39 (41.9) | 33 (70.2) | 0.001 |
| Targetoid appearance | 37 (26.4) | 33 (35.5) | 4 (8.5) | |
| Nontargetoid hypointensity | 31 (22.1) | 21 (22.6) | 10 (21.3) | |
| HBP appearance | ||||
| Targetoid appearance | 74 (52.9) | 55 (59.1) | 19 (40.4) | 0.036 |
| Nontargetoid hypointensity | 66 (47.1) | 38 (40.9) | 28 (59.6) | |
| Diffusion-weighted imaging appearance† | n = 133 | n = 90 | n = 43 | 0.005 |
| Targetoid restriction | 73 (54.9) | 55 (61.1) | 18 (41.9) | |
| Marked diffusion restriction | 25 (18.8) | 19 (21.1) | 6 (14.0) | |
| Restriction but nontargetoid nor marked | 35 (26.3) | 16 (17.8) | 19 (44.2) | |
| Vascular invasion | 82 (58.6) | 41 (44.1) | 41 (87.2) | <0.001 |
| Multiplicity | 28 (20.0) | 14 (15.1) | 14 (29.8) | 0.040 |
| Regional lymph node metastasis | 29 (20.7) | 15 (16.1) | 14 (29.8) | 0.060 |
| Necrosis or mucin | 52 (37.1) | 33 (35.5) | 19 (40.4) | 0.568 |
Unless otherwise indicated, data are numbers of patients, with percentages in parentheses. Categorical variables were compared using the χ2 test or Fisher exact test, as appropriate. APHE, arterial phase hyperenhancement.
*
Data are continuous variables, reported as median (range) values, and were compared using the Student's t test.
†
Percentages were calculated after excluding the nonassessable (missing) cases.